Abstract
In women with preexisting diabetes and nephropathy or microalbuminuria, it is important to deliver careful preconception counselling to assess the risk for the mother and the foetus, for optimizing glycaemic status and to adjust medical treatment. If serum creatinine is normal in early pregnancy, kidney function is often preserved during pregnancy, but complications such as severe preeclampsia and preterm delivery are still common. Perinatal mortality is now comparable with that in women with diabetes and normal kidney function. Besides strict glycaemic control before and during pregnancy, early and intensive antihypertensive treatment is important to optimize pregnancy outcomes. Methyldopa, labetalol, nifedipine and diltiazem are considered safe, whereas angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers should be stopped before or at confirmation of pregnancy. Supplementation with folic acid in early pregnancy and low-dose aspirin from 10 to 12 weeks reduces the risk of adverse pregnancy outcomes. During breastfeeding, several ACE inhibitors are considered safe.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Ekbom P, Damm P, Feldt-Rasmussen B, Feldt-Rasmussen U, Molvig J, Mathiesen ER. Pregnancy outcome in type 1 diabetic women with microalbuminuria. Diabetes Care. 2001;24:1739–44.
Klemetti MM, Laivuori H, Tikkanen M, Nuutila M, Hiilesmaa V, Teramo K. Obstetric and perinatal outcome in type 1 diabetes patients with diabetic nephropathy during 1988–2011. Diabetologia. 2015;58:678–86. The largest to date population-based study of clinical care in pregnant women with type 1 diabetes and diabetic nephropathy. Hypertension management was suboptimal and severe hypertension, nephrotic proteinuria, preeclampsia and preterm delivery occurred in a high proportion of women.
Damm JA, Asbjornsdottir B, Callesen NF, Mathiesen JM, Ringholm L, Pedersen BW, et al. Diabetic nephropathy and microalbuminuria in pregnant women with type 1 and type 2 diabetes: prevalence, antihypertensive strategy, and pregnancy outcome. Diabetes Care. 2013;36:3489–94. Recent large clinical study showing that the prevalence of diabetic nephropathy and microalbuminuria in early pregnancy was similar in type 2 and type 1 diabetes and that pregnancy outcome was comparable regardless type of diabetes.
Nielsen LR, Damm P, Mathiesen ER. Improved pregnancy outcome in type 1 diabetic women with microalbuminuria or diabetic nephropathy: effect of intensified antihypertensive therapy? Diabetes Care. 2009;32:38–44.
Landon MB. Diabetic nephropathy and pregnancy. Clin Obstet Gynecol. 2007;50:998–1006.
McCance DR, Holmes VA, Maresh MJ, Patterson CC, Walker JD, Pearson DW, et al. Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trial. Lancet. 2010;376:259–66.
Murphy HR, Steel SA, Roland JM, Morris D, Ball V, Campbell PJ, et al. Obstetric and perinatal outcomes in pregnancies complicated by Type 1 and Type 2 diabetes: influences of glycaemic control, obesity and social disadvantage. Diabet Med. 2011;28:1060–7.
Clausen TD, Mathiesen E, Ekbom P, Hellmuth E, Mandrup-Poulsen T, Damm P. Poor pregnancy outcome in women with type 2 diabetes. Diabetes Care. 2005;28:323–8.
Cundy T, Slee F, Gamble G, Neale L. Hypertensive disorders of pregnancy in women with Type 1 and Type 2 diabetes. Diabet Med. 2002;19:482–9.
Jensen DM, Damm P, Ovesen P, Molsted-Pedersen L, Beck-Nielsen H, Westergaard JG, et al. Microalbuminuria, preeclampsia, and preterm delivery in pregnant women with type 1 diabetes: results from a nationwide Danish study. Diabetes Care. 2010;33:90–4.
Kitzmiller, Montoro: Diabetic Nephropathy and Pregnancy. In Managing Preexisting Diabetes and Pregnancy. Kitzmiller, Ed. American Diabetes Association, 2008, p. 374–386
Mathiesen ER, Ringholm L, Feldt-Rasmussen B, Clausen P, Damm P. Obstetric nephrology: pregnancy in women with diabetic nephropathy--the role of antihypertensive treatment. Clin J Am Soc Nephrol. 2012;7:2081–8.
Piccoli GB, Clari R, Ghiotto S, Castelluccia N, Colombi N, Mauro G, et al. Type 1 diabetes, diabetic nephropathy, and pregnancy: a systematic review and meta-study. Rev Diabet Stud. 2013;10:6–26. Systematic review and meta-study on diabetic nephropathy and pregnancy in type 1 diabetes from 1980 to 2012.
Bar J, Chen R, Schoenfeld A, Orvieto R, Yahav J, Ben-Rafael Z, et al. Pregnancyoutcome in patients with insulin dependent diabetes mellitus and diabetic nephropathy treated with ACE inhibitors before pregnancy. J Pediatr Endocrinol Metab. 1999;12:659–65.
Carr DB, Koontz GL, Gardella C, Holing EV, Brateng DA, Brown ZA, et al. Diabetic nephropathy in pregnancy: suboptimal hypertensive control associated with preterm delivery. Am J Hypertens. 2006;19:513–9.
Dunne FP, Chowdhury TA, Hartland A, Smith T, Brydon PA, McConkey C, et al. Pregnancy outcome in women with insulin-dependent diabetes mellitus complicated by nephropathy. QJM. 1999;92:451–4.
Gordon M, Landon MB, Samuels P, Hissrich S, Gabbe SG. Perinatal outcome and long-term follow-up associated with modern management of diabetic nephropathy. Obstet Gynecol. 1996;87:401–9.
Kimmerle R, Zass RP, Cupisti S, Somville T, Bender R, Pawlowski B, et al. Pregnancies in women with diabetic nephropathy: long-term outcome for mother and child. Diabetologia. 1995;38:227–35.
Reece EA, Coustan DR, Hayslett JP, Holford T, Coulehan J, O’Connor TZ, et al. Diabetic nephropathy: pregnancy performance and fetomaternal outcome. Am J Obstet Gynecol. 1988;159:56–66.
Reece EA, Leguizamon G, Homko C. Stringent controls in diabetic nephropathy associated with optimization of pregnancy outcomes. J Matern Fetal Med. 1998;7:213–6.
Sorensen VR, Mathiesen ER, Heaf J, Feldt-Rasmussen B. Improved survival rate in patients with diabetes and end-stage renal disease in Denmark. Diabetologia. 2007;50:922–9.
Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348:2285–93.
Parving HH, Smidt UM, Hommel E, Mathiesen ER, Rossing P, Nielsen F, et al. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis. 1993;22:188–95.
Standards of medical care in diabetes--2015: summary of revisions. Diabetes Care 38 Suppl:S4, 2015
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy the collaborative study group. N Engl J Med. 1993;329:1456–62.
Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ. 1991;303:81–7.
Mathiesen ER, Ronn B, Storm B, Foght H, Deckert T. The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study. Diabet Med. 1995;12:482–7.
Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ. 1999;319:24–5.
Estacio RO, Coll JR, Tran ZV, Schrier RW. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens. 2006;19:1241–8.
Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354:2443–51.
Tabacova S, Little R, Tsong Y, Vega A, Kimmel CA. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol Drug Saf. 2003;12:633–46.
Rossing K, Jacobsen P, Hommel E, Mathiesen E, Svenningsen A, Rossing P, et al. Pregnancy and progression of diabetic nephropathy. Diabetologia. 2002;45:36–41.
Bell R, Glinianaia SV, Tennant PW, Bilous RW, Rankin J. Peri-conception hyperglycaemia and nephropathy are associated with risk of congenital anomaly in women with pre-existing diabetes: a population-based cohort study. Diabetologia. 2012.
Sibai: Diabetic nephropathy in pregnancy. In A practical manual of diabetes in pregnancy. Blackwell Publishing, 2008, p. 153–156
Khoury JC, Miodovnik M, LeMasters G, Sibai B. Pregnancy outcome and progression of diabetic nephropathy. What’s next? J Matern Fetal Neonatal Med. 2002;11:238–44.
Clausen P, Ekbom P, Damm P, Feldt-Rasmussen U, Nielsen B, Mathiesen ER, et al. Signs of maternal vascular dysfunction precede preeclampsia in women with type 1 diabetes. J Diabetes Complications. 2007;21:288–93.
Yu Y, Jenkins AJ, Nankervis AJ, Hanssen KF, Scholz H, Henriksen T, et al. Anti-angiogenic factors and pre-eclampsia in type 1 diabetic women. Diabetologia. 2009;52:160–8.
Wang A, Rana S, Karumanchi SA: P. the role of angiogenic factors in its pathogenesis. Physiol (Bethesda ). 2009;24:147–58.
Fox NS, Roman AS, Saltzman DH, Hourizadeh T, Hastings J, Rebarber A. Risk factors for preeclampsia in twin pregnancies. Am J Perinatol. 2014;31:163–6.
Lucovnik M, Tul N, Verdenik I, Novak Z, Blickstein I. Risk factors for preeclampsia in twin pregnancies: a population-based matched case–control study. J Perinat Med. 2012;40:379–82.
Sibai BM, Hauth J, Caritis S, Lindheimer MD, Macpherson C, Klebanoff M, et al. Hypertensive disorders in twin versus singleton gestations national institute of child health and human development network of maternal-fetal medicine units. Am J Obstet Gynecol. 2000;182:938–42.
Weissgerber TL, Mudd LM. Preeclampsia and diabetes. Curr Diab Rep. 2015;15:9.
Itskovitz J, Rubattu S, Levron J, Sealey JE. Highest concentrations of prorenin and human chorionic gonadotropin in gestational sacs during early human pregnancy. J Clin Endocrinol Metab. 1992;75:906–10.
Nielsen AH, Schauser KH, Poulsen K. Current topic: the uteroplacental renin-angiotensin system. Placenta. 2000;21:468–77.
Al KH, Nasrat H, Broughton PF. A prospective, longitudinal study of the renin-angiotensin system, prostacyclin and thromboxane in the first trimester of normal human pregnancy: association with birthweight. Hum Reprod. 2005;20:3157–62.
Sealey JE, Itskovitz-Eldor J, Rubattu S, James GD, August P, Thaler I, et al. Estradiol- and progesterone-related increases in the renin-aldosterone system: studies during ovarian stimulation and early pregnancy. J Clin Endocrinol Metab. 1994;79:258–64.
Ringholm L, Pedersen-Bjergaard U, Thorsteinsson B, Boomsma F, Damm P, Mathiesen ER. A high concentration of prorenin in early pregnancy is associated with development of pre-eclampsia in women with type 1 diabetes. Diabetologia. 2011;54:1615–9.
McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9–13.
Tulevski II, Groenink M, van der Wall EE, van Veldhuisen DJ, Boomsma F, Stoker J, et al. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: correlation between plasma neurohormones and right ventricular dysfunction. Heart. 2001;86:27–30.
Borghi C, Cicero AF, Degli ED, Immordino V, Bacchelli S, Rizzo N, et al. Hemodynamic and neurohumoral profile in patients with different types of hypertension in pregnancy. Intern Emerg Med. 2011;6:227–34.
Resnik JL, Hong C, Resnik R, Kazanegra R, Beede J, Bhalla V, et al. Evaluation of B-type natriuretic peptide (BNP) levels in normal and preeclamptic women. Am J Obstet Gynecol. 2005;193:450–4.
Ringholm L, Pedersen-Bjergaard U, Thorsteinsson B, Boomsma F, Damm P, Mathiesen ER. Atrial Natriuretic Peptide (ANP) in early pregnancy is associated with development of preeclampsia in type 1 diabetes. Diabetes Res Clin Pract. 2011;93:e106–9.
Ekbom P, Damm P, Andersson AM, Skakkebaek NE, Feldt-Rasmussen U, Mathiesen ER. Serum levels of activin A and inhibin A are not related to the increased susceptibility to pre-eclampsia in type I diabetic pregnancies. Acta Obstet Gynecol Scand. 2006;85:143–7.
Holmes VA, Young IS, Patterson CC, Maresh MJ, Pearson DW, Walker JD, et al. The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes. Diabetes Care. 2013;36:3671–7. Large assessment of the association between circulating anti-angiogenic factors and risk of preeclampsia in women with type 1 diabetes.
Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol. 2011;31:33–46.
Holmes VA, McCance DR. Could antioxidant supplementation prevent pre-eclampsia? Proc Nutr Soc. 2005;64:491–501.
McCance DR, Holmes VA, Maresh MJ, Patterson CC, Walker JD, Pearson DW, et al. Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trial. Lancet. 2010;376:259–66.
Biesenbach G, Stoger H, Zazgornik J. Influence of pregnancy on progression of diabetic nephropathy and subsequent requirement of renal replacement therapy in female type I diabetic patients with impaired renal function. Nephrol Dial Transplant. 1992;7:105–9.
Purdy LP, Hantsch CE, Molitch ME, Metzger BE, Phelps RL, Dooley SL, et al. Effect of pregnancy on renal function in patients with moderate-to-severe diabetic renal insufficiency. Diabetes Care. 1996;19:1067–74.
Ringholm L, Mathiesen ER, Kelstrup L, Damm P. Managing type 1 diabetes mellitus in pregnancy--from planning to breastfeeding. Nat Rev Endocrinol. 2012;8:659–67.
Boulot P, Chabbert-Buffet N, d’Ercole C, Floriot M, Fontaine P, Fournier A, et al. French multicentric survey of outcome of pregnancy in women with pregestational diabetes. Diabetes Care. 2003;26:2990–3.
Evers IM, de Valk HW, Visser GH. Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. BMJ. 2004;328:915.
Ekbom P, Damm P, Nogaard K, Clausen P, Feldt-Rasmussen U, Feldt-Rasmussen B, et al. Urinary albumin excretion and 24-hour blood pressure as predictors of pre-eclampsia in Type I diabetes. Diabetologia. 2000;43:927–31.
Hanson U, Persson B. Epidemiology of pregnancy-induced hypertension and preeclampsia in type 1 (insulin-dependent) diabetic pregnancies in Sweden. Acta Obstet Gynecol Scand. 1998;77:620–4.
Holmes VA, Young IS, Patterson CC, Pearson DW, Walker JD, Maresh MJ, et al. Optimal glycemic control, pre-eclampsia, and gestational hypertension in women with type 1 diabetes in the diabetes and pre-eclampsia intervention trial. Diabetes Care. 2011;34:1683–8.
Hiilesmaa V, Suhonen L, Teramo K. Glycaemic control is associated with pre-eclampsia but not with pregnancy-induced hypertension in women with type I diabetes mellitus. Diabetologia. 2000;43:1534–9.
Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. Diabetes Care. 2007;30:1920–5.
Jensen DM, Korsholm L, Ovesen P, Beck-Nielsen H, Moelsted-Pedersen L, Westergaard JG, et al. Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care. 2009;32:1046–8.
Nielsen LR, Pedersen-Bjergaard U, Thorsteinsson B, Johansen M, Damm P, Mathiesen ER. Hypoglycemia in pregnant women with type 1 diabetes: predictors and role of metabolic control. Diabetes Care. 2008;31:9–14.
Secher AL, Mathiesen ER, Andersen HU, Peter D, Lene R. Severe hypoglycemia in pregnant women with type 2 diabetes-A relevant clinical problem. Diabetes Res Clin Pract. 2013;102:e17–8.
Management of diabetes from preconception to the postnatal period. summary of NICE guidance. BMJ. 2008;336:714–7.
Lauszus FF, Gron PL, Klebe JG. Pregnancies complicated by diabetic proliferative retinopathy. Acta Obstet Gynecol Scand. 1998;77:814–8.
Vestgaard M, Ringholm L, Laugesen CS, Rasmussen KL, Damm P, Mathiesen ER. Pregnancy-induced sight-threatening diabetic retinopathy in women with Type 1 diabetes. Diabet Med. 2010;27:431–5.
Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116:402–14.
Duley L, Henderson-Smart DJ, Meher S, King JF: Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev CD004659, 2007
Catalano, Conway: Management of pregnancy complications. In Managing preexisting diabetes and pregnancy. 2008, p. 578–584
Wilson RD, Davies G, Desilets V, Reid GJ, Summers A, Wyatt P, et al. The use of folic acid for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can. 2003;25:959–73.
Capel I, Corcoy R. What dose of folic acid should be used for pregnant diabetic women? Diabetes Care. 2007;30:e63.
Kazmin A, Garcia-Bournissen F, Koren G. Risks of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can. 2007;29:906–8.
Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension. 2012;60:444–50.
Porta M, Hainer JW, Jansson SO, Malm A, Bilous R, Chaturvedi N, et al. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials. Diabetologia. 2011;54:1298–303.
Tennant PW, Glinianaia SV, Bilous RW, Rankin J, Bell R. Should women with diabetic nephropathy considering pregnancy continue ACE inhibitor or angiotensin II receptor blocker therapy until pregnancy is confirmed? Reply to Lewis G and Maxwell AP [letter]. Diabetologia. 2014;57:1084–5.
Nielsen LR, Muller C, Damm P, Mathiesen ER. Reduced prevalence of early preterm delivery in women with Type 1 diabetes and microalbuminuria--possible effect of early antihypertensive treatment during pregnancy. Diabet Med. 2006;23:426–31.
Khandelwal M, Kumanova M, Gaughan JP, Reece EA. Role of diltiazem in pregnant women with chronic renal disease. J Matern Fetal Neonatal Med. 2002;12:408–12.
Magee LA, Ornstein MP, Von DP. Fortnightly review: management of hypertension in pregnancy. BMJ. 1999;318:1332–6.
Colstrup M, Mathiesen ER, Damm P, Jensen DM, Ringholm L. Pregnancy in women with type 1 diabetes: have the goals of St. Vincent declaration been met concerning foetal and neonatal complications? J Matern Fetal Neonatal Med. 2013;26:1682–6. Review of all population-based studies published within the last 10 years comparing pregnancy outcomes in women with T1DM and women from the background population.
Pedersen BW, Ringholm L, Damm P, Tabor A, Sogaard K, Hellmuth E, Mathiesen ER: Stable fetal hemodynamics measured by Doppler flow after initiation of anti-hypertensive treatment with methyldopa in pregnant women with diabetes. J Matern Fetal Neonatal Med 1–4, 2015. First study to document the safety of initiating antihypertensive treatment in late pregnancy on fetal outcomes.
Folic MM, Jankovic SM, Varjacic MR, Folic MD. Effects of methyldopa and nifedipine on uteroplacental and fetal hemodynamics in gestational hypertension. Hypertens Pregnancy. 2012;31:31–9.
Montan S, Anandakumar C, Arulkumaran S, Ingemarsson I, Ratnam SS. Effects of methyldopa on uteroplacental and fetal hemodynamics in pregnancy-induced hypertension. Am J Obstet Gynecol. 1993;168:152–6.
Montan S, Anandakumar C, Arulkumaran S, Ingemarsson I, Ratnam S. Randomised controlled trial of methyldopa and isradipine in preeclampsia--effects on uteroplacental and fetal hemodynamics. J Perinat Med. 1996;24:177–84.
Von DP, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 2000;355:87–92.
American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics. 1994;93:137–50.
Beardmore KS, Morris JM, Gallery ED. Excretion of antihypertensive medication into human breast milk: a systematic review. Hypertens Pregnancy. 2002;21:85–95.
Shannon ME, Malecha SE, Cha AJ. Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) and lactation: an update. J Hum Lact. 2000;16:152–5.
Podymow T, August P. Antihypertensive drugs in pregnancy. Semin Nephrol. 2011;31:70–85.
Shannon ME, Malecha SE, Cha AJ. Beta blockers and lactation: an update. J Hum Lact. 2000;16:240–5.
Podymow T, Joseph G. Preconception and pregnancy management of women with diabetic nephropathy on angiotensin converting enzyme inhibitors. Clin Nephrol. 2015;83:73–9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Lene Ringholm, Julie Agner Damm, Marianne Vestgaard, Peter Damm and Elisabeth R. Mathiesen declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article contains studies with human subjects performed by all authors. The studies have been approved by the appropriate national research ethics committee and have been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
This article does not contain any studies with animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Microvascular Complications—Nephropathy
Rights and permissions
About this article
Cite this article
Ringholm, L., Damm, J.A., Vestgaard, M. et al. Diabetic Nephropathy in Women With Preexisting Diabetes: From Pregnancy Planning to Breastfeeding. Curr Diab Rep 16, 12 (2016). https://doi.org/10.1007/s11892-015-0705-3
Published:
DOI: https://doi.org/10.1007/s11892-015-0705-3